News or noise?

Article Abstract:

More questions are raised about the level and quality of the information disclosed to the market by the biotech managers and directors, who jump to make the most of the revival of investor interest in the biotech sector. Announcements by some small science companies listed on the Australian Stock Exchange, suggest that some directors have liberally interpreted their disclosure requirements.

Management dynamics, Personnel administration, Management, Human resource management, Forecasts and trends, Market trend/market analysis, Company business management, Company personnel management, Corporate officers, Disclosure of information

---

Biotech in the waiting room

Article Abstract:

If the recent rally in the stock prices of CSL, Cochlear and ResMed on Australian Stock Exchange (ASE) is any indication, the prospects for the biotechnology sector in 2005 are very bright. With the exception of these three stocks, the sector had registered a growth of 3% against the 23% rise of overall stocks recorded on ASE in 2004.

Analysis, Stocks, Stock prices, Industry forecasts

---

The biotech boom

Article Abstract:

Issues are discussed concerning the growing demand in Australia for volatile biotechnology stocks by investors hoping the sector will be more reliable than the recent dot.com phenomenon.

Similar abstracts:

• Abstracts: Strategies revisited in the face of growing fears about mail. Winter Olympics begin for TV marketers
• Abstracts: Keeping it in the family. Indian summer. Big, private - and getting bigger
• Abstracts: Views from the top. The economy's strength is on the home front. Global statistical lag is significant
• Abstracts: Why business fears Beazley. Taking the lead in soft shoe .... Labor's big ask: 'Trust us'
• Abstracts: Farmers lose debate. Competition germinates. Who's milking whom?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.